COVINA, Calif., Oct. 25, 2012 /PRNewswire/ -- StemCyte, Inc. is proud to announce that StemCyte Taiwan has met the eligibility requirements for accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT), an organization helping to assure the highest standards in cellular therapy practices. StemCyte Taiwan’s accreditation achievement matches its continued FACT accreditation at its Covina, California North American lab. The dual lab accreditation is further evidence of StemCyte’s commitment to being an industry leader by maintaining the highest level of quality controls across their global enterprise.
“Patients and families are at the forefront of our minds in everything we do at StemCyte. We owe them our best and operating at the highest standard is an imperative,” said Ken Giacin, StemCyte’s Chairman. “StemCyte Taiwan Cord Blood Bank takes great pride in receiving FACT accreditation knowing it demonstrates our strong focus on excellence in all aspects of what we do, patient care and lab practices alike,” said Charles Lu, President, StemCyte Taiwan.
FACT accredited organizations voluntarily comply with rigorous industry standards. They are the only set of accreditation requirements addressing both clinical and laboratory practices.
“StemCyte is committed to producing and delivering cellular therapy products that consistently meet the highest quality standards for safety, identity, purity and potency for patients in need,” said StemCyte’s Global Medical Director, Dr. Wise Young, MD, PhD. “StemCyte Taiwan’s accreditation to match our California lab’s ongoing accreditation demonstrates our global commitment to delivering superior quality and consistency to the doctors, patients and parents we serve.”
About StemCyte, Inc.
Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 1,750 cord blood products for over 70 life-threatening diseases to over 200 leading transplant centers worldwide. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies. The Company supports the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, and the development of trials investigating regenerative spinal cord therapies. StemCyte is one of the only for-profit companies contracted by the US Department of HHS to help contribute clinical grade cord blood units to the public National Cord Blood Inventory for unrelated transplants. Its headquarters are in Covina, CA. To learn more visit www.StemCyte.com.
SOURCE StemCyte, Inc.
